TITLE:
Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients

CONDITION:
Kidney Transplantation

INTERVENTION:
Certican

SUMMARY:

      The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican)
      administered to pediatric renal transplant recipients, and to provide additional safety
      data.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: N/A to 16 Years
Criteria:

        Inclusion Criteria:

          -  Male and female patients no more than 16 years of age.

          -  Patients receiving a primary cadaveric or non-HLA identical living donor (related or
             unrelated) renal transplant.

          -  The graft must be functional within 48 hours post transplantation.

        Exclusion Criteria:

          -  Cold ischemia time greater than 40 hours.

          -  Patients who are recipients of multiple solid organ transplants, including dual and
             en bloc kidneys, or who have previously received transplanted organs.

          -  Patients with panel reactive T cell antibodies of 50 % or higher at the last
             assessment before transplantation.
      
